Boehringer terminates Alzheimer’s candidate after Phase 2 failure
February 12, 2018Research and Development, Sales and Marketing Alzheimer's, Boehringer Ingelheim, dementia, pharma
Boehringer Ingelheim has announced its intention to halt development of its candidate BI 409306 in the treatment of Alzheimer’s after …
MannKind entices Lilly VP to CMO role
February 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, Mannkind, biotech, drugs, pharma, pharmaceutical
MannKind, the California-based biotech, announced that David Kendall would be joining its team as Chief Medical Officer and would be …
SFO bribery investigation into GSK opens old wounds
February 9, 2018Medical Communications GSK, biotech, drugs, pharma, pharmaceutical
A small titbit of information was buried within GSK’s financials this week, which threatens to bring up old news that …
Top Ten most popular articles on Pharmafile.com this week
February 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Allergan, Antibiotics, Avycaz, Elastagen, FDA, GSK, India, J&J, JJ, Nektar Therapeutics, Novartis, Theravance, artificial intelligence, pharma
It’s top ten time again. This week, among our most popular stories was the worrying news that, accoridng to research …
Fujifilm partners with Takeda, stepping into regenerative medicine
February 9, 2018Medical Communications, Research and Development Fujifilm, Takeda, biotech, drugs, pharma, pharmaceutical
Fujifilm has been steadily building up its regenerative medicines, with several acquisitions of companies that hold expertise in the area …
FDA expands J&J Zytiga combo’s indication to include castration-sensitive prostate cancer
February 9, 2018Medical Communications, Sales and Marketing Cancer, FDA, J&J, JJ, Janssen, Johnson & Johnson, Zytiga, pharma
Johnson & Johnson has announced that Zytiga (abiraterone acetate) in combination with prednisone has been awarded FDA approval in the …
Migraine drug bad news hits a weakened Teva
February 9, 2018Medical Communications, Sales and Marketing CGRP, Teva, biotech, drugs, pharma, pharmaceutical
The cacophony of bad news that Teva has received in 2017 really needs no retelling, anyone following the story of …
Stada poaches Novartis exec for fifth CEO in two years
February 8, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, Stada, appointment
Stada has revealed its new CEO as Peter Goldschmidt, the current head of North American operations at Novartis’ generics and …
Celgene Executive Chairman Bob Hugin retires
February 8, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Fresh from its acquisition of Juno Therapeutics, Celgene announced that its Executive Chairman Bob Hugin was to retire effective 5 …
New Year, new goals
February 8, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CRUK, Cancer Research UK, Chiesi, EMA, FDA, Genetic Alliance, pharma
With the New Year begun in earnest, Pharmafocus speaks to a range of players in pharma and the life sciences …
Dr Reddy’s hit by yet another recall, of 80,000+ bottles
February 8, 2018Sales and Marketing Dr Reddy's, FDA, biotech, drugs, pharma, pharmaceutical
Dr Reddy’s Laboratories problem with ensuring products reach the market at a quality the FDA deems acceptable is no secret …
FDA approves Gilead’s Biktarvy for HIV as Viiv Healthcare launches patent lawsuit
February 8, 2018Sales and Marketing Biktarvy, FDA, GSK, Gilead, HIV, Pfizer, Shionogi, US, ViiV Healthcare, descovy, pharma
Gilead has announced that its daily single-tablet therapy Biktarvy has received FDA approval for HIV-1 infection.
Novartis tastes own medicine, Advair generic delayed
February 8, 2018Sales and Marketing FDA, Novartis, biotech, drugs, pharma, pharmaceutical
Novartis had not been frontrunner to receive approval for its generic version of GSK’s Advair – lagging behind Mylan’s generic …
Theravance seals potential $1bn deal with J&J
February 8, 2018Sales and Marketing Johnson & Johnson, Theravance Biopharma, biotech, drugs, pharma, pharmaceutical
The JAK inhibitor field is beginning to heat up – AbbVie is soon to enter Phase 3 with its predicted …
Biogen halts Tysabri trial after failure in acute ischemic stroke
February 8, 2018Research and Development Biogen, Tysabri, multiple sclerosis, pharma, stroke, trial failure
Biogen has halted its investigation into the efficacy of its humanised monoclonal antibody Tysabri (natalizumab) in the treatment of acute …
Astellas confirms Kenji Yasukawa as new President and CEO
February 7, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, appointment
Japanese pharmaceutical firm Astellas has announced that its Board of Directors has approved the selection of current Chief Strategy Officer …
CEO gets the axe: Arcturus relieve Payne of position
February 7, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Arcturus, biotech, drugs, pharma, pharmaceutical
Early in February, Arcturus Therapeutics revealed that it had let its CEO, Joseph Payne, go and had replaced him as …
J&J’s apalutamide shows strength in non-metastatic prostate cancer
February 7, 2018Research and Development J&J, JJ, Johnson & Johnson, pharma, prostate cancer
Johnson & Johnson unveiled new data at the ASCO Genitourinary Cancer symposium which demonstrated that its androgen receptor antagonist apalutamide …
Array’s melanoma therapy blasts Roche’s out of water
February 7, 2018Research and Development Array Biopharma, Pierre Fabre, Roche, biotech, drugs, melanoma, pharma, pharmaceutical
Array Biopharma suffered a serious knock back in early 2017 when its plan to commercialise its drug, binimetinib, were derailed …
Allergan bolsters skincare portfolio with Elastagen acquisition for $95 million
February 7, 2018Research and Development, Sales and Marketing Allergan, Elastagen, M&A, MA, pharma
Pharma’s M&A train keeps on going as news breaks that Allergan has picked up University of Sydney spin-off Elastagen for …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
